DarioHealth’s cardiometabolic solution in diabetes featured in published study

DarioHealth announced the publication of a new study in the peer-reviewed journal Frontiers in Endocrinology. The study demonstrates the effectiveness of Dario’s cardiometabolic solution for members living with diabetes or prediabetes and depression. Approximately 18%-25% of people living with type 2 diabetes experience depression. Dario’s cardiometabolic solution includes integrated mental health support. The new research used retrospective data from 989 users who regularly tracked their steps levels and BG levels for 12 months using Dario’s cardiometabolic solution. Dario members who reported depression exhibited higher average BG levels compared to those without depression. In both cases members experienced a significant decrease in BG levels during the initial 4 months of platform usage, followed by a stable period during months 4-12 of the monitoring. A statistically significant association was found between the depression status and BG levels. Also, a statistically significant association was found between the depression status and monthly average number of steps. The new study supports the incorporation of walking into treatment protocols as a cost-effective and accessible intervention strategy to improve glycemic control and alleviate depressive symptoms in people living with T2D and depression.